Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
复制标题
DOI：
10.1016/bs.aivir.2016.07.001
复制
发表时间：
2017
影响因子：
--
通讯作者：
Sutter G
中科院分区：
文献类型：
--
作者：
Volz A;Sutter G
经过安全性测试的改良安卡拉牛痘病毒（MVA）被批准为第三代天花疫苗，并作为一种有效的载体系统，用于开发新的候选疫苗，以对抗传染病和癌症。历史上，MVA是通过在牛痘病毒株安卡拉的原代鸡细胞中连续组织培养传代而开发的，并在临床上用于避免常规天花疫苗接种的不良副作用。MVA适应了在禽类细胞中的生长，失去了在哺乳动物宿主中复制的能力，并且缺乏正痘病毒用来征服其宿主（细胞）环境的许多基因。作为一种生物学特性良好的突变病毒，MVA有助于基础研究，以阐明痘病毒宿主相互作用因子的功能。MVA疫苗作为非常安全的病毒载体，在各种临床前感染模型中具有免疫原性和保护性。多种重组MVA目前正在进行针对人类免疫缺陷病毒、结核分枝杆菌或恶性疟原虫的疫苗接种的临床试验。MVA载体疫苗平台的多功能性很容易通过快速开发用于针对中东呼吸综合征等新出现的感染进行免疫的实验性疫苗来证明。最近的进展包括高致病性禽流感病毒H5N1或埃博拉病毒的重组MVA生产抗原的临床试验的有希望的结果。本文综述了MVA作为一种独特的牛痘病毒株的研究进展，并讨论了MVA作为痘病毒生物学研究工具或安全的病毒载体疫苗的前景，以挑战现有和未来的疫苗学瓶颈。
Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines against infectious diseases and cancer. Historically, MVA was developed by serial tissue culture passage in primary chicken cells of vaccinia virus strain Ankara, and clinically used to avoid the undesirable side effects of conventional smallpox vaccination. Adapted to growth in avian cells MVA lost the ability to replicate in mammalian hosts and lacks many of the genes orthopoxviruses use to conquer their host (cell) environment. As a biologically well-characterized mutant virus, MVA facilitates fundamental research to elucidate the functions of poxvirus host-interaction factors. As extremely safe viral vectors MVA vaccines have been found immunogenic and protective in various preclinical infection models. Multiple recombinant MVA currently undergo clinical testing for vaccination against human immunodeficiency viruses, Mycobacterium tuberculosis or Plasmodium falciparum. The versatility of the MVA vector vaccine platform is readily demonstrated by the swift development of experimental vaccines for immunization against emerging infections such as the Middle East Respiratory Syndrome. Recent advances include promising results from the clinical testing of recombinant MVA-producing antigens of highly pathogenic avian influenza virus H5N1 or Ebola virus. This review summarizes our current knowledge about MVA as a unique strain of vaccinia virus, and discusses the prospects of exploiting this virus as research tool in poxvirus biology or as safe viral vector vaccine to challenge existing and future bottlenecks in vaccinology.
登录
查看更多内容
DOI：
10.3390/v6072735
发表时间：
2014-07-17
期刊：
Viruses
影响因子：
--
作者：
Altenburg AF;Kreijtz JH;de Vries RD;Song F;Fux R;Rimmelzwaan GF;Sutter G;Volz A
通讯作者：
Volz A
影响因子：
64.5
作者：
ALCAMI, A;SMITH, GL
通讯作者：
SMITH, GL
影响因子：
5.4
作者：
Bender, BS;Rowe, CA;Small, PA
通讯作者：
Small, PA
影响因子：
3.5
作者：
Antoine, G;Scheiflinger, F;Dorner, F
通讯作者：
Dorner, F
影响因子：
64.8
作者：
BLANCOU, J;KIENY, MP;DESMETTRE, P
通讯作者：
DESMETTRE, P